Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SULT1A1 | P50225 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 11/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984564 | 0.89 | KDM4E (0.40) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL1984565 | 0.89 | KDM4E (0.40) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL12422465 | 0.88 | NPC1 (0.39) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL12422107 | 0.80 | MAPT (0.49) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL1984147 | 0.79 | SULT1A1 (0.41) | NPC1MAPTRAB9ASULT1A1APP | |
| SCHEMBL1984149 | 0.79 | SULT1A1 (0.41) | NPC1MAPTRAB9ASULT1A1APP | |
| SCHEMBL1984117 | 0.76 | MAPT (0.46) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL1984115 | 0.76 | MAPT (0.46) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL12422466 | 0.69 | APP (0.42) | NPC1MAPTKDM4ERAB9ANPSR1 | |
| SCHEMBL2194030 | 0.69 | SULT1A1 (0.45) | NPC1MAPTRAB9ASULT1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | NPC1 1265/4885MAPT 1/4885KDM4E 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.